About us

Scientific manager: Philippe Ravassard ​

Philippe Ravassard trained as a student in Biochemistry at the “Ecole Normale Supérieure de Cachan”. ​

He obtained his PhD in Jacques Mallet’s laboratory as a developmental neurobiologist. ​

He joined McGill University in Montreal for post-doctoral studies (JP Julien’s lab, 1997-98). ​

He is leading the Biotechnology & Biotherapy team at the ICM since 2011. He obtained the “Habilitation à diriger la recherche“ (HDR) in 2014. ​

He was first to clone in rat the transcription factor Neurogenin3 (ngn3). This factor was next identified as the key regulator of endocrine differentiation in the pancreas. ​

Missions / Search projects : ​

Philippe Ravassard’s team focuses on identifying and characterizing genetic components implicated in the etiopathology of Parkinson’s disease. ​

Using in vitro and in vivo modeling, we aim to validate the identified coding and non-coding elements of the genome for the future development of new therapeutic strategies.

Operational manager : Laetitia Strehl

Laetitia STREHL holds a Master’s degree in R&D Biotechnology from University Pierre et Marie Curie (2003) and comes from academic research. In the past, Laetitia worked on research projects using cell culture approaches, at Necker Institute and Ecole Normale Supérieure. At the end of 2010, she joined the facility as operational manager and since then actively contributed in establishing and developing core facility activities and services.

• Email: laetitia.strehl@icm-institute.org
• Phone: 01 57 27 40 37

Assistant Engineer : Manon Lamontagne

License in biotechnologies in ETSL (2023)

Océane Ribault

Work-study Master’s student (M1-M2) in Sorbonne University

Philippe Ravassard

Team «Molecular Pathophysiology of Parkinson’s disease »​

ALBERTO BACCI​

Team «Cellular physiology of cortical microcircuits »​

Jaime DE JUAN san

The Diane barrière Chair “Molecular physiology of synaptic bioenergetics”

violetta zujovic

Team “Myelin plasticity and regeneration”

Delphine Bohl

Modeling ALS using pluripotent induced pluripotent stem cells (iPS).

Isabelle Le Roux

Team Genetics and Development of brain tumors.